CA1336683C - Diagnosis and treatment of double-stranded rna deficiency states - Google Patents

Diagnosis and treatment of double-stranded rna deficiency states

Info

Publication number
CA1336683C
CA1336683C CA000576351A CA576351A CA1336683C CA 1336683 C CA1336683 C CA 1336683C CA 000576351 A CA000576351 A CA 000576351A CA 576351 A CA576351 A CA 576351A CA 1336683 C CA1336683 C CA 1336683C
Authority
CA
Canada
Prior art keywords
dsrna
composition defined
rnase
mismatched
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000576351A
Other languages
English (en)
French (fr)
Inventor
William A. Carter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HEM Pharmaceuticals Corp
Original Assignee
HEM Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HEM Pharmaceuticals Corp filed Critical HEM Pharmaceuticals Corp
Application granted granted Critical
Publication of CA1336683C publication Critical patent/CA1336683C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Saccharide Compounds (AREA)
CA000576351A 1987-09-04 1988-09-01 Diagnosis and treatment of double-stranded rna deficiency states Expired - Fee Related CA1336683C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9352387A 1987-09-04 1987-09-04
US093,523 1987-09-04

Publications (1)

Publication Number Publication Date
CA1336683C true CA1336683C (en) 1995-08-15

Family

ID=22239406

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000576351A Expired - Fee Related CA1336683C (en) 1987-09-04 1988-09-01 Diagnosis and treatment of double-stranded rna deficiency states

Country Status (15)

Country Link
JP (1) JPH0825884B2 (pt)
KR (1) KR890005277A (pt)
CN (1) CN1031651A (pt)
AU (3) AU2186488A (pt)
CA (1) CA1336683C (pt)
DK (1) DK491088A (pt)
FI (1) FI884069A (pt)
IL (1) IL87664A (pt)
NO (1) NO883868L (pt)
NZ (1) NZ226033A (pt)
OA (1) OA08911A (pt)
PH (1) PH26320A (pt)
PT (1) PT88415B (pt)
RU (1) RU2001917C1 (pt)
ZA (1) ZA886581B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1088344C (zh) * 1997-10-17 2002-07-31 青岛市卫生防疫站 富硒或富锌蚯蚓干粉或提取物的制造方法
US20060035859A1 (en) * 2003-05-16 2006-02-16 Hemispherx Biopharma Treating severe and acute viral infections

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) * 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
JPS57200310A (en) * 1981-05-26 1982-12-08 Merck & Co Inc Local application of interferon inducer
AU1820388A (en) * 1987-07-17 1989-01-19 Hem Research, Inc. Double stranded rna correction of aberrant metabolic pathways associated with uncontrolled tumor cell and virus growth cycles

Also Published As

Publication number Publication date
NO883868L (no) 1989-03-06
NZ226033A (en) 1999-08-30
ZA886581B (en) 1989-04-26
AU1001495A (en) 1995-03-30
AU2186488A (en) 1989-03-09
NO883868D0 (no) 1988-08-30
CN1031651A (zh) 1989-03-15
AU1736692A (en) 1992-07-30
IL87664A (en) 1995-03-15
DK491088A (da) 1989-03-05
FI884069A0 (fi) 1988-09-02
PT88415A (pt) 1989-07-31
JPH01131118A (ja) 1989-05-24
DK491088D0 (da) 1988-09-02
JPH0825884B2 (ja) 1996-03-13
IL87664A0 (en) 1989-02-28
KR890005277A (ko) 1989-05-13
PH26320A (en) 1992-04-29
FI884069A (fi) 1989-03-05
PT88415B (pt) 1992-10-30
RU2001917C1 (ru) 1993-10-30
OA08911A (en) 1989-10-31

Similar Documents

Publication Publication Date Title
EP0306347B1 (en) Diagnosis of double-stranded RNA deficiency states
US5593973A (en) Treatment of viral hepatitis with mismatched dsRNA
AU2003283647B2 (en) Use of CPG oligonucleotides in the treatment of hepatitis C virus infection
JP4335311B2 (ja) プロテアーゼインヒビターの生物学的及び抗ウイルス活性を改善する方法
US5132292A (en) Treatment of viral hepatitis
EP0347501A1 (en) Modulation of lymphokine-resistant cellular states by dsRNAs
JP2017506232A (ja) 腫瘍を治療するための阻害性オリゴヌクレオチド
CA1336683C (en) Diagnosis and treatment of double-stranded rna deficiency states
US12005120B2 (en) Galnac conjugated modified oligonucleotides as miR-122 inhibitor having HCV antiviral activity with reduced hyperbilirubinemia side-effect
AU692433B2 (en) Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
CA2259041A1 (en) Method of treating hiv infection and related secondary infections thereof
WO2014137929A1 (en) Methods for treating hepatitis c virus
AU724056B2 (en) Diagnosis and treatment of double stranded deficiency states
US7052676B2 (en) Methods for inhibition of HIV replication using a small molecule inhibitor
JP2013513655A (ja) 成人ｔ細胞白血病／リンパ腫の処置における使用のための方法、医薬組成物及びキット
JP2007534672A (ja) マクロファージ転移阻害因子阻害剤を用いる、１型糖尿病処置
US5194245A (en) Diagnosis of viral hepatitis
JPS63309200A (ja) Ｈｉｖの測定方法
Sarin et al. Treatment of AIDS with drugs targeted to inhibit different stages of the HIV life cycle
RU2021810C1 (ru) Способ воздействия на развитие заболевания, вызванного hiv-вирусом или вирусом, вызывающим сходную биохимическую или клиническую картину
RU2003334C1 (ru) Способ лечени больных с опухол ми
Hirasawa et al. Adenine-induced selective apoptosis toward HIV chronically infected cells in vitro
JPH10506120A (ja) Ｈｉｖの複製を阻害するムラミルペプチド組成物
JP2015199762A (ja) 成人ｔ細胞白血病／リンパ腫の処置における使用のための方法、医薬組成物及びキット
JP2015512900A (ja) 特別な患者の遺伝子亜型分集団のｈｃｖ感染症を治療するための併用療法

Legal Events

Date Code Title Description
MKLA Lapsed